CDH2 and neoplasm: The presence of mesenchymal markers, such as vimentin (24.5% of patients) and N-cadherin (13.7% of patients) [88] suggests that EMT plays a crucial role in the aggressive nature of this tumor subtype, potentially contributing to poorer prognosis and increased metastatic potential.